Trial Profile
Phase I Study of Relapsed CD30 Expressing Lymphoma Treated With Multi-Dose CD30 CAR T Cells (RELY-30)
Status:
Recruiting
Phase of Trial:
Phase I
Latest Information Update: 11 Mar 2023
Price :
$35
*
At a glance
- Drugs TT 11 (Primary) ; Cyclophosphamide; Fludarabine
- Indications Hodgkin's disease; Non-Hodgkin's lymphoma
- Focus Adverse reactions
- Acronyms RELY-30
- 06 Mar 2023 Planned End Date changed from 1 Feb 2036 to 1 Feb 2040.
- 16 Dec 2022 Planned number of patients changed from 66 to 60.
- 20 Jul 2022 Planned primary completion date changed from 1 Apr 2022 to 1 Apr 2026.